CoronaryAtlas logo
CoronaryAtlas
Sclerostin
Pathway / Off-pathway / systemic markers

Sclerostin

SOSTprotein

Sclerostin, a Wnt antagonist from bone, reflects post-MI cardiac remodeling and systemic stress responses independent of atherothrombotic progression.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleBone-derived remodeling marker; systemic axis distinct from atherothrombotic cascade.
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
37
C — confounder / Type-II
58
A — assay feasibility
68
E — evidence strength
22
T1DI (composite)
6
Specificity differential (R−C)-20.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(2)